<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28430010</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>07</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>12</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1097-9867</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Pharmaceutical development and technology</Title>
          <ISOAbbreviation>Pharm Dev Technol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Prolonged injectable formulation of Nafarelin using in situ gel combination delivery system.</ArticleTitle>
        <Pagination>
          <StartPage>132</StartPage>
          <EndPage>144</EndPage>
          <MedlinePgn>132-144</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/10837450.2017.1321662</ELocationID>
        <Abstract>
          <AbstractText>The principal purpose of the present study was to prepare and characterize a complex drug delivery system consisting of Nafarelin-poly (3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanoparticles (NPs) in combination with sodium alginate/poloxamer 407 in situ gel. Nafarelin-loaded PHBV NPs were prepared via double emulsion solvent evaporation technique. Box-Behnken Response Surface Methodology was utilized to optimize NPs. Mean particle size, polydispersity index (PDI), entrapment efficiency (EE), and drug loading (DL) of the optimized NPs were measured. Incorporation of Nafarelin within NPs was proven by differential scanning calorimetry (DSC). The combination delivery system (CDS) was prepared by adding Nafarelin-loaded PHBV NPs to sodium alginate/poloxamer 407 solution followed by physical mixing. Morphological properties of Nafarelin-loaded PHBV NPs and CDS were evaluated by SEM. Rheological properties were employed to investigate the effects of alginate concentration on sol-gel transition temperature. The release profile of Nafarelin from both PHBV NPs and CDS were individually assessed. The cumulative release percentage from CDS was significantly lower than Nafarelin released from PHBV NPs. Based on the favorable results in this study, the CDS consisting of sodium alginate/poloxamer 407 loaded with PHBV NPs could be a promising candidate for designing a long-lasting formulation of Nafarelin.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Alizadeh</LastName>
            <ForeName>Behnoush</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>a Department of Pharmaceutics, Faculty of Pharmacy , Tehran University of Medical Science , Tehran , Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bahari Javan</LastName>
            <ForeName>Nika</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>a Department of Pharmaceutics, Faculty of Pharmacy , Tehran University of Medical Science , Tehran , Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Akbari Javar</LastName>
            <ForeName>Hamid</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>a Department of Pharmaceutics, Faculty of Pharmacy , Tehran University of Medical Science , Tehran , Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Khoshayand</LastName>
            <ForeName>Mohammad Reza</ForeName>
            <Initials>MR</Initials>
            <AffiliationInfo>
              <Affiliation>b Department of Drug and Food Control and Pharmaceutical Quality Assurance Research Center, Faculty of Pharmacy , Tehran University of Medical Science , Tehran , Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dorkoosh</LastName>
            <ForeName>Farid</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>a Department of Pharmaceutics, Faculty of Pharmacy , Tehran University of Medical Science , Tehran , Iran.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>c Medical Biomaterial Research Center (MBRC), Tehran University of Medical Science , Tehran , Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>05</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Pharm Dev Technol</MedlineTA>
        <NlmUniqueID>9610932</NlmUniqueID>
        <ISSNLinking>1083-7450</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000464">Alginates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005782">Gels</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006603">Hexuronic Acids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011091">Polyesters</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C052620">poly(3-hydroxybutyrate)-co-(3-hydroxyvalerate)</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>106392-12-5</RegistryNumber>
          <NameOfSubstance UI="D020442">Poloxamer</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1X0094V6JV</RegistryNumber>
          <NameOfSubstance UI="D017274">Nafarelin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8A5D83Q4RW</RegistryNumber>
          <NameOfSubstance UI="D020723">Glucuronic Acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000464" MajorTopicYN="N">Alginates</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002626" MajorTopicYN="N">Chemistry, Pharmaceutical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004337" MajorTopicYN="N">Drug Carriers</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005782" MajorTopicYN="N">Gels</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020723" MajorTopicYN="N">Glucuronic Acid</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006603" MajorTopicYN="N">Hexuronic Acids</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007267" MajorTopicYN="N">Injections</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017274" MajorTopicYN="N">Nafarelin</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010316" MajorTopicYN="N">Particle Size</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020442" MajorTopicYN="N">Poloxamer</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011091" MajorTopicYN="N">Polyesters</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Nafarelin</Keyword>
        <Keyword MajorTopicYN="N">combination delivery system</Keyword>
        <Keyword MajorTopicYN="N">poloxamer 407</Keyword>
        <Keyword MajorTopicYN="N">poly (3-hydroxybutyrate-co-3-hydroxyvalerate)</Keyword>
        <Keyword MajorTopicYN="N">sodium alginate</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>7</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28430010</ArticleId>
        <ArticleId IdType="doi">10.1080/10837450.2017.1321662</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28430010</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>07</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>12</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1097-9867</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Pharmaceutical development and technology</Title>
          <ISOAbbreviation>Pharm Dev Technol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Prolonged injectable formulation of Nafarelin using in situ gel combination delivery system.</ArticleTitle>
        <Pagination>
          <StartPage>132</StartPage>
          <EndPage>144</EndPage>
          <MedlinePgn>132-144</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/10837450.2017.1321662</ELocationID>
        <Abstract>
          <AbstractText>The principal purpose of the present study was to prepare and characterize a complex drug delivery system consisting of Nafarelin-poly (3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanoparticles (NPs) in combination with sodium alginate/poloxamer 407 in situ gel. Nafarelin-loaded PHBV NPs were prepared via double emulsion solvent evaporation technique. Box-Behnken Response Surface Methodology was utilized to optimize NPs. Mean particle size, polydispersity index (PDI), entrapment efficiency (EE), and drug loading (DL) of the optimized NPs were measured. Incorporation of Nafarelin within NPs was proven by differential scanning calorimetry (DSC). The combination delivery system (CDS) was prepared by adding Nafarelin-loaded PHBV NPs to sodium alginate/poloxamer 407 solution followed by physical mixing. Morphological properties of Nafarelin-loaded PHBV NPs and CDS were evaluated by SEM. Rheological properties were employed to investigate the effects of alginate concentration on sol-gel transition temperature. The release profile of Nafarelin from both PHBV NPs and CDS were individually assessed. The cumulative release percentage from CDS was significantly lower than Nafarelin released from PHBV NPs. Based on the favorable results in this study, the CDS consisting of sodium alginate/poloxamer 407 loaded with PHBV NPs could be a promising candidate for designing a long-lasting formulation of Nafarelin.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Alizadeh</LastName>
            <ForeName>Behnoush</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>a Department of Pharmaceutics, Faculty of Pharmacy , Tehran University of Medical Science , Tehran , Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bahari Javan</LastName>
            <ForeName>Nika</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>a Department of Pharmaceutics, Faculty of Pharmacy , Tehran University of Medical Science , Tehran , Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Akbari Javar</LastName>
            <ForeName>Hamid</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>a Department of Pharmaceutics, Faculty of Pharmacy , Tehran University of Medical Science , Tehran , Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Khoshayand</LastName>
            <ForeName>Mohammad Reza</ForeName>
            <Initials>MR</Initials>
            <AffiliationInfo>
              <Affiliation>b Department of Drug and Food Control and Pharmaceutical Quality Assurance Research Center, Faculty of Pharmacy , Tehran University of Medical Science , Tehran , Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dorkoosh</LastName>
            <ForeName>Farid</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>a Department of Pharmaceutics, Faculty of Pharmacy , Tehran University of Medical Science , Tehran , Iran.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>c Medical Biomaterial Research Center (MBRC), Tehran University of Medical Science , Tehran , Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>05</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Pharm Dev Technol</MedlineTA>
        <NlmUniqueID>9610932</NlmUniqueID>
        <ISSNLinking>1083-7450</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000464">Alginates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005782">Gels</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006603">Hexuronic Acids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011091">Polyesters</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C052620">poly(3-hydroxybutyrate)-co-(3-hydroxyvalerate)</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>106392-12-5</RegistryNumber>
          <NameOfSubstance UI="D020442">Poloxamer</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1X0094V6JV</RegistryNumber>
          <NameOfSubstance UI="D017274">Nafarelin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8A5D83Q4RW</RegistryNumber>
          <NameOfSubstance UI="D020723">Glucuronic Acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000464" MajorTopicYN="N">Alginates</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002626" MajorTopicYN="N">Chemistry, Pharmaceutical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004337" MajorTopicYN="N">Drug Carriers</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005782" MajorTopicYN="N">Gels</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020723" MajorTopicYN="N">Glucuronic Acid</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006603" MajorTopicYN="N">Hexuronic Acids</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007267" MajorTopicYN="N">Injections</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017274" MajorTopicYN="N">Nafarelin</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010316" MajorTopicYN="N">Particle Size</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020442" MajorTopicYN="N">Poloxamer</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011091" MajorTopicYN="N">Polyesters</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Nafarelin</Keyword>
        <Keyword MajorTopicYN="N">combination delivery system</Keyword>
        <Keyword MajorTopicYN="N">poloxamer 407</Keyword>
        <Keyword MajorTopicYN="N">poly (3-hydroxybutyrate-co-3-hydroxyvalerate)</Keyword>
        <Keyword MajorTopicYN="N">sodium alginate</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>7</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28430010</ArticleId>
        <ArticleId IdType="doi">10.1080/10837450.2017.1321662</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
